
GYRE Stock Forecast & Price Target
GYRE Analyst Ratings
Bulls say
Gyre Therapeutics Inc. is strategically positioned in the market with its acquisition of generic nintedanib, which enhances its operational capital and strengthens its leadership in therapies for idiopathic pulmonary fibrosis (IPF) as well as liver fibrosis. The company's commercial offerings, including ETUARY and its pipeline of drug candidates targeting various organ diseases, reflect a robust revenue-generating capability, particularly in the Chinese market. With a focus on innovative treatments, Gyre is set to capitalize on growing demand within the anti-inflammatory and anti-fibrotic drug segments, contributing to a positive long-term financial outlook.
Bears say
Gyre Therapeutics Inc faces a challenging outlook primarily due to depressed forward multiples reflecting current market volatility, which may impact investor confidence. The company’s commercial sales of pirfenidone in China are not included in valuation assessments, given that these revenues have plateaued and are not from growth-stage assets. Additionally, concerns regarding cash burn arise from the varying stages of development programs and the uncertainty of offsetting revenues from potential partnerships or collaborations.
This aggregate rating is based on analysts' research of Gyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
GYRE Analyst Forecast & Price Prediction
Start investing in GYRE
Order type
Buy in
Order amount
Est. shares
0 shares